Meningitis Final
Meningitis Final
Meningitis Final
D
Definition of meningitis-
DEFINITION
-Acute &diffuse inflammation of the CNS with
primary
. involvement of the meninges following
infection.
Etiology
During the first 2 mo of life – maternal flora and the environment
Groups B and D streptococci
Listeria monocytogenes
N. meningitides
H. influenzae type b
Immunocompromisation
Neuroanatomical defects (e.g. dermal sinus,
neurosurgery)
Parameningeal infection (e.g. sinusitis, mastoiditis)
Environmental (e.g. day-care centers, household
contact, travel to endemic regions, crowding, poverty)
especially meningococci & H. influenzae
Cont…
In General
lack of immunity to specific pathogens associated with
young age
recent colonization with pathogenic bacteria,
○ meningoccocus
○ rapidly progressive manifestations of shock, purpura, DIC,
and
○ reduced levels of consciousness with progression to coma or
death within 24 hr
Cont…
Subacute onset (more common)
○ Hib , pneumoccocal , meningoccocal
symptoms
○ followed by nonspecific signs of CNS
○ Myalgia , arthralgia
days
are initiated
Shock ,DIC
Visual impairment
Behavioral problems
Mental retardation
○ Pneumococcal meningitis
CSF
○ Seizure occurring after 4days of therapy
presentation
A. Antibiotic prophylaxis (chemoprophylaxis)
- For N. meningitidis
All close contacts of patients with meningococcal
meningitis regardless of age or immunization status
Penicillin does not eradicate nasopharyngeal carriage;
patients treated with penicillin should receive
prophylaxis before hospital discharge
(Rifampin 10mg/kg/dose every 12 hr
(maximum dose of 600 mg) for 2 days or ceftriaxone single IM
injection or Ciprofloxacin (500 mg orally as a single dose) may be given to
persons ≥18 yr of age )
Cont…
- For Hib
For ALL household contacts, including adults
- Pneumococcal meningitis
No Chemoprophylaxis needed.
Cont…
B. Vaccination
- For N. menin : A quadrivalent (A,C,Y, W-135)
conjugated vaccine
: Recommended for high-risk
children older than 2 yr
- For Hib : Conjugate vaccine
- For Pneumococcal : Against S. pneumoniae for all children younger
than 2 yr of age with high risk of invasive pneumococcal infections
- Functional or anatomic asplenia and
- Immunocompromised pt
Thank you